Jazz Pharmaceuticals raises 2026 revenue guidance to $4.60 billion to $4.75 billion

Earnings
โดย Seeking Alpha·Read original
Summary · why it matters

Jazz Pharmaceuticals raised its full-year 2026 total revenue guidance to $4.60 billion to $4.75 billion, citing limited generic impact and strong Xywav performance. The company reported record quarterly revenue of $1.21 billion, a 16% year-over-year increase, driven by double-digit growth across key promoted brands including Xywav, Epidiolex, and Zepzelca. Management expressed high confidence in the upcoming August 25 PDUFA date for zanidatamab in first-line HER2-positive metastatic GEA and said teams are fully prepared to launch. Non-GAAP adjusted EPS was $5.71, which included IPR&D charges totaling $0.94, and operating cash flow reached $824 million in the first half of the year. The company also modestly increased SG&A guidance to support strategic investments and updated share count guidance to 69 million to 70 million shares.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketDXNews